title: CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART.
abstract: To determine whether viral load rebounds during HAART impact on CD4+ T cell recovery and immune reconstitution, we studied a prospective cohort of 355 antiretroviral naive patients enrolled to be randomized in a trial of three strategies of induction/maintenance HAART. The extent of immune reconstitution in blood through 72 weeks of antiretroviral treatment was evaluated. Lymphocyte subset markers (CD4, CD8, CD45RA, CD62L, CD16, CD19), activation markers (HLA-DR, CD38, CD25) were performed by cytometry analysis. Our results showed that plasma HIV-1 RNA was suppressed to below 500 copies per ml through week 72 in 240 patients (group 1) while the remaining 115 patients experienced at least one viral rebound (group 2). At baseline, CD4 cell count was higher and HIV-1 RNA was lower in group 1 than in group 2. Over 72 weeks, mean increase in CD4+ T cell count was 0.32 cell/mm3/day in group 1 and only 0.14 cell/mm3/day in group 2 (P < 0.0001). However, the patterns of changes in CD4+ and CD8+ T cell subsets during therapy were very similar across the two groups with only subtle and very limited differences. We conclude that permanent control of HIV replication could be necessary for faster immune reconstitution.
authors.affiliation: Unité d'Immuno-Hématologie et d'Immuno-Pathologie, Institut Pasteur, Paris, France. scott@pasteur.fr
authors.forename: D
authors.initials: D
authors.lastname: Scott-Algara
authors.forename: J P
authors.initials: JP
authors.lastname: Aboulker
authors.forename: C
authors.initials: C
authors.lastname: Durier
authors.forename: E
authors.initials: E
authors.lastname: Badell
authors.forename: F
authors.initials: F
authors.lastname: Marcellin
authors.forename: M
authors.initials: M
authors.lastname: Prud'homme
authors.forename: C
authors.initials: C
authors.lastname: Jouanne
authors.forename: V
authors.initials: V
authors.lastname: Meiffredy
authors.forename: F
authors.initials: F
authors.lastname: Brun-Vezinet
authors.forename: G
authors.initials: G
authors.lastname: Pialoux
authors.forename: F
authors.initials: F
authors.lastname: Raffi
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D008297:Male; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D014766:Viremia / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D014779:Virus Replication / Q000187:drug effects
chemical_list: D012367:RNA, Viral